Washington, D.C. 20549

	                              FORM 6-K

             13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
                                  OF 1934

             Dated: May 16, 2002

                       Commission file number 0-21392

                            AMARIN CORPORATION PLC
            (Exact name of Registrant as Specified in its Charter)

                      (Jurisdiction of Incorporation or
                            organization of Issuer)

                                7 Curzon Street
                             London W1J 5HG, England
                      (Address of Principal Executive Offices)

     Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.

            [X] Form 20-F            [ ] Form 40-F

     Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

            [ ] Yes                  [X] No


Material Events

(a) Amarin Corporation plc announces drug research
agreement with Eiffel Technologies Ltd. to improve oral
drug delivery

          This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.

           Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                         AMARIN CORPORATION PLC

                        By:/s/Richard A B Stewart
                          Richard A B Stewart
                          Chief Executive Officer

Date: May 16, 2002

                                         Index to

Exhibit Item                  Sequentially Numbered Page

(a) Material Event description-             4
Amarin Corporation plc announces drug
research agreement with Eiffel
Technologies Ltd. to improve oral drug delivery



Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2440

Christine Cussen
Chief Executive Officer
Eiffel Technologies Limited
Phone: +61 (0) 3 9629 8022


Research Collaboration to Combine Firms'
Controlled-Release and Supercritical Fluid
Bioengineering Technologies Could Dramatically
Improve Current and Future Pharmaceuticals

LONDON, United Kingdom, May 16, 2002 -- Amarin
Corporation plc (NASDAQ: AMRN) today announced that
its subsidiary, Amarin Development AB, has entered
into an agreement with Eiffel Research and
Development Pty Ltd, a subsidiary company of Eiffel
Technologies Limited (EIF, ASX) to establish a
strategic research partnership.  The partnership is
designed to improve extended-release pharmaceutical
products by combining Amarin's proprietary drug
delivery technologies with Eiffel's Supercritical
Fluid (SCF) Drug bioengineering technologies.

The initial phase of the collaboration, where each
party will be responsible for individual costs,
will involve applying Eiffel's SCF technology to
the production of sub-micron sized drug particles
of a currently undisclosed drug substance.  Those
drug particles will then be incorporated into
Amarin's Diffusion Controlled Vesicle (DCV)
controlled-release technology.  If successful, the
new combination technology would potentially
improve the extended-release of drugs that are
difficult to deliver orally because of their low
solubility in water.

The new combination technology could potentially
improve the extended release of drugs that are
difficult to deliver orally because of their low
absorption into the bloodstream.  The new
technology could be applied to new compounds or
drugs currently on the market but not available in
extended-release formulations due to dissolution
issues that negatively impact bioavailability.
Further details of the agreement were not

"Amarin is committed to enhancing the value of our
technology platforms through innovative research
partnerships and collaborations," said Rick
Stewart, chief executive officer of Amarin
Corporation.  "This new, combination technology has
the potential to both improve the quality of
controlled release drugs on the market, as well as
broaden the range of drug molecules that can be
effectively delivered orally.  Most importantly, we
believe that this combination could provide
significant value to our patients and customers, as
well as helping to advance our internal drug
development efforts in the key areas of neurology
and pain management."

"We look forward to a productive and successful
relationship with Amarin," said Christine Cussen,
chief executive officer of Eiffel Technologies
Limited.  "Each partner brings a unique and highly-
valued technology to this venture.  In combination,
these technologies potentially offer significantly
enhanced utility in the delivery of

Amarin's DCV system is used for the controlled
release of substances for periods up to 24 hours.
The patented technology consists of a tablet core
incorporating the active ingredient surrounded by a
water-insoluble membrane containing minute
particles of water-soluble material.  The soluble
particles dissolve when the tablet is ingested,
resulting in a macro-porous film structure through
which drug is released at a steady rate.  Principal
licensees for the technology include Pharmacia,
Sanofi-Synthelabo and Tanabe Seiyaku.  More than
three billion tablets have been manufactured and
used effectively by patients in more than thirty

Eiffel's SCF drug bioengineering technologies can
be used to improve the physical characteristics of
drugs and proteins to enhance their absorption and
bioavailability.  Under performing, poorly soluble
drugs account for over 40 percent of the world
pharmaceutical market, currently valued at
approximately US$39 billion in 2000.  Eiffel's SCF
technologies can be used to improve drug
effectiveness, reduce drug cost and dosing, extend
patent life of drugs prior to generic competition
and provide more patient friendly delivery systems,
such as once a day orals, long acting sustained
release formulations, and inhalationals to replace
injections. Eiffel Research and Development Pty Ltd
currently has alliances with, Sheffield
Pharmaceuticals Inc and BattellePharma, Inc.

Amarin Corporation plc is a specialty
pharmaceutical company focused on neurology and
pain management.  The company plans to become a
leader in these therapeutic categories by providing
innovative products and solutions that address
significant unmet medical needs.  For press
releases and other Company information, visit our
website at  Amarin Development
AB, based in Malmo, Sweden, is a wholly owned
subsidiary of Amarin Corporation plc.  It is
dedicated to the research and development of
advanced controlled release and site-specific
technology solutions to create improved outcome
formulations of both new and existing drugs.

Eiffel Technologies Limited, through its subsidiary
company Eiffel Research & Development Pty Ltd, is a
biomedical, bioengineering company focused on
improving the performance and delivery of
pharmaceuticals, proteins and peptides. Based in
Melbourne, the company is dedicated to the
development and commercialization of SCF drug
technologies to improve therapeutic outcomes and
patient administration of new and currently
marketed pharmaceuticals. For further information
on the Company, visit our web site at

Statements in this press release that are not
historical facts are forward-looking statements
that involve risks and uncertainties which may
cause the Company's actual results in future
periods to be materially different from any
performance suggested herein.  Such risks and
uncertainties include, without limitation, risks
associated with the inherent uncertainty of
pharmaceutical research, product development and
commercialisation, the impact of competitive
products and patents, as well as other risks and
uncertainties detailed from time to time in
periodic reports.  For more information, please
refer to Amarin Corporation's Annual Report for
2001 on Form 20-F and its Form 6-Ks as filed with
the U.S. Securities and Exchange Commission.  The
Company assumes no obligation to update information
on its expectations.